Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel
NYSEAMERICAN:OGEN

Oragenics Q1 2026 Earnings Report

Oragenics logo
$0.59 -0.01 (-1.33%)
As of 04:10 PM Eastern
ProfileEarnings History

Oragenics EPS Results

Actual EPS
-$0.51
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oragenics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oragenics Announcement Details

Quarter
Q1 2026
Date
5/8/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oragenics Earnings Headlines

Oragenics (NYSEAMERICAN:OGEN) Shares Down 1.5% - Should You Sell?
June 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30820038
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
May 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/oragenics-present-sidoti-micro-cap-124500288.html
Important SpaceX PREDICTION
The biggest IPO in stock market history could go live as soon as June 12th — but trading legend Jon Najarian says investors are about to miss the real opportunity. A little-known FCC filing Elon quietly submitted earlier this year has caught Morgan Stanley's attention — and they estimate it could be worth $40 trillion. That's larger than Tesla, xAI, Starlink, X, Neuralink, and SpaceX combined.tc pixel
June 10 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
May 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297513/0/en/oragenics-to-present-at-sidoti-s-micro-cap-virtual-investor-conference-may-20-21.html
ORAGENICS PROVIDES INVESTOR UPDATE
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296615/0/en/oragenics-provides-investor-update.html
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290005/0/en/oragenics-signs-letter-of-intent-to-license-cardiodialysis-technology-from-sigyn-therapeutics-to-target-tbi-induced-systemic-inflammation.html
See More Oragenics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oragenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oragenics and other key companies, straight to your email.

About Oragenics

Oragenics (NYSEAMERICAN:OGEN) is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures. In addition to its dental portfolio, Oragenics is advancing Ogi-04™, a therapeutic candidate for the prevention and treatment of oral mucositis, a common and painful side effect of cancer therapy. Oragenics’ research pipeline also includes earlier-stage programs aimed at broad-spectrum anti-infective applications.

Founded in 1996, Oragenics has built a foundation of proprietary peptide and gene-based platforms that support its drug discovery and development efforts. The company operates primarily in the United States but seeks to establish strategic collaborations to extend its reach into additional markets. Oragenics is listed on the New York Stock Exchange under the ticker symbol OGEN.

Oragenics is led by President and Chief Executive Officer Todd Korth, whose leadership and financial expertise have guided the company’s strategic direction and operational execution. The management team combines scientific experience with regulatory and commercial know-how to advance the company’s clinical programs toward potential commercialization.

View Oragenics Profile
Earnings Tools